In the pharmaceutical industry, the main communication risk is no longer just that a message goes unnoticed. The real challenge is that a poorly calibrated piece triggers regulatory questions, competitor objections or damages the organization’s credibility. In markets such as Peru and Mexico, where scrutiny of the communication of health-related products is increasing, the line between an effective strategy and a possible accusation of misleading advertising can be thinner than many companies imagine.
For pharmaceutical laboratories, medical device companies and healthcare companies, communicating with precision has become a strategic asset. The challenge is to build persuasive messages without falling into exaggerated promises, ambiguous claims or testimonials that could be interpreted as unsubstantiated scientific evidence.
Trust has become a regulatory asset
Corporate reputation has always been important for the pharmaceutical industry, but today it is also closely linked to regulatory compliance.
The Edelman Trust Barometer 2025 reveals that perceptions of business ethics have a direct impact on levels of trust in organizations. Among groups with the highest levels of social discontent, companies are perceived as significantly less ethical and less competent than among those with higher levels of institutional trust.
For a pharmaceutical laboratory, this means that any inconsistency between what it communicates and what it can actually demonstrate is not only a legal risk. It can also become a reputational threat that affects relationships with patients, healthcare professionals, distributors, investors and authorities.
Misleading advertising in healthcare: a risk that goes beyond fines
In traditional sectors, an exaggerated campaign can result in consumer complaints. In healthcare, the consequences are usually greater.
Phrases such as:
- “The best treatment on the market”.
- “Guaranteed results”.
- “No side effects”.
- “Definitive cure”.
- “Approved by specialists”.
They can raise questions if there is no robust scientific evidence to support them or if they lead to incorrect interpretations about the product’s real properties.
The problem does not always lie in an explicit lie. Often it arises from omissions, incomplete comparisons or messages that exaggerate benefits while downplaying limitations.
That is why the real fear for communication teams is not just a crisis on social media. It is that an advertising piece, a digital content item or a corporate statement triggers regulatory reviews or leads to competitor objections questioning the truthfulness of the message.
The practices that most expose pharmaceutical laboratories
Digital transformation has multiplied the touchpoints with patients and healthcare professionals. However, it has also widened the opportunities for making mistakes.
Among the riskiest practices are:
Testimonials without sufficient context
Testimonials can be powerful tools of communication, but also a frequent source of questions when they present extraordinary results without clarifying conditions, limitations or supporting evidence.
Influencers and content creators
Collaboration with opinion leaders requires strict protocols. A lack of transparency about sponsored content can create misleading perceptions and affect the brand’s credibility.
Images that create unrealistic expectations
Visual editing is part of modern communication, but when it substantially alters reality it can create expectations the product cannot meet.
Omission of relevant information
In pharmaceutical communication, omitting also communicates. Failing to include usage restrictions, warnings or specific conditions can be as problematic as making incorrect claims.
Improper use of artificial intelligence
The ease of generating text, images and videos with AI increases the risk of spreading messages that are technically attractive but scientifically imprecise or insufficiently validated.
What the strongest brands can teach the healthcare sector
Recent history shows that authenticity tends to produce better results than exaggeration.
Dove’s “Real Beauty” campaign is one of the best-known examples of how abandoning unrealistic standards can strengthen the connection with audiences. Instead of building impossible expectations, the brand chose to depict real situations and reinforce values associated with authenticity.
Similarly, Burger King developed campaigns focused on showing its products with dimensions closer to reality, using transparency as a differentiator from the competition.
Although they belong to different industries, both cases leave a relevant lesson for pharmaceutical laboratories: credibility can become a competitive advantage when the market is saturated with promises.
Five principles for communicating pharmaceutical products without crossing the line
Corporate communication teams can significantly reduce their risks by applying simple but rigorous principles:
- Validate every claim with verifiable scientific backing.
- Involve regulatory teams from the early stages of content creation.
- Avoid absolute superlatives such as “the best”, “unique” or “guaranteed”.
- Implement specific protocols for influencers and external spokespeople.
- Periodically review digital content to ensure it remains compliant with regulations.
The key is not to communicate less. It is to communicate with greater precision.
The competitive advantage of transparency
A study cited by PwC showed a significant gap between the trust companies believe they generate and the trust consumers actually perceive. While most business leaders consider their organizations highly trustworthy, consumers’ perception is usually considerably lower. In addition, a large majority say they would stop buying from a company they no longer trust.
In an environment where trust has become a determining factor for corporate reputation, pharmaceutical communication can no longer be limited to maximizing visibility. It must help strengthen credibility.
For pharmaceutical laboratories operating in Peru and Mexico, the challenge is not only to comply with regulations. It is to build a narrative capable of generating sustained trust without compromising the integrity of the message.
Because in the healthcare industry, the best communication strategy remains the same: say exactly what can be demonstrated.
Altavoz Comunicaciones supports companies in the healthcare, pharmaceutical and corporate sectors in designing communication strategies that combine impact, regulatory compliance and long-term reputation building.
